The TRAILBLAZER-ALZ 2 Clinical Research Study is evaluating the safety and effectiveness of an investigational drug for people with early symptomatic Alzheimer’s disease.
The study involves people who have memory loss that has gotten worse over the last last six months or more. If you are experiencing memory loss or struggling to perform complex tasks, you may pre-qualify.
Participants are randomly assigned into one of two groups. They receive either the investigational drug or a placebo.
If you qualify, participation can last up to 2.5 years, with up to 26 appointments with the study center.